In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%. At the ...

Proficio Capital Partners cranked up its position in Vertex Pharmaceuticals by 46.6% during the fourth quarter, grabbing 978 ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Corp (NVRO – Research Report), Globus ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.70% to $511.74 Monday, on what proved to be an all-around great trading ...

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for ...

This was the stock's second consecutive day of losses.

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...